Last reviewed · How we verify

NCT03923309

Oncologic Risk of Rectal Preservation Against Medical Advice After Chemoradiotherapy for Rectal Cancer

Completed Last updated 22 April 2019
What this trial tests

trial in Rectal Cancer in 142 participants. Completed in 30 December 2017.

Timeline
1 May 2016
Primary endpoint
30 December 2017
30 December 2017

Quick facts

Lead sponsorSeoul National University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment142
Start date1 May 2016
Primary completion30 December 2017
Estimated completion30 December 2017
Sites3 locations across South Korea

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

18 and older, any sex, with Rectal Cancer or Chemoradiation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Though refusal of radical surgery was often happened in rectal cancer patient after neoadjuvant chemoradiotherapy, little is currently known about the actual oncologic outcome of it. Thus the investigators designed this study to compare the oncologic outcome of unintended rectal preservation with intended rectal preservation by surgeon.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03923309.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing